Weiss Ratings Reiterates “Sell (E+)” Rating for Equillium (NASDAQ:EQ)

Equillium (NASDAQ:EQ)‘s stock had its “sell (e+)” rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Equillium to a “sell” rating in a research report on Friday, September 5th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $1.00.

Equillium Stock Up 6.0%

Shares of EQ opened at $1.41 on Friday. The stock has a market capitalization of $83.90 million, a P/E ratio of -2.52 and a beta of 1.53. The firm has a fifty day simple moving average of $1.55 and a two-hundred day simple moving average of $0.82. Equillium has a twelve month low of $0.27 and a twelve month high of $2.35.

Equillium (NASDAQ:EQ) last posted its earnings results on Thursday, August 14th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Sell-side analysts expect that Equillium will post 0.14 EPS for the current fiscal year.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.